As part of the Coronavis project, the AIDS Research Institute (IrsiCaixa) and the Atenció Primària Metropolitana Nord of the Institut Català de la Salut (ICS) are carrying out exhaustive monitoring of the degree of protection of the elderly; specifically, those who live in residences.
The project, which is partially financed by the Fundació Glòria Soler, demonstrated last August the need to revaccinate older people who had received two doses of the vaccine but had not had COVID-19. Now, the team begins the study of immunity against SARS-CoV-2 after this group received the third dose of the vaccine, with the aim of understanding how their protection evolves.
“It is necessary to study what protection older people have at all times, since their immune aging makes them more vulnerable to severe COVID-19,” explains Marta Massanella, lead researcher. Now, the team has collected blood samples from the 83 people who have already received the third dose of the vaccine and who are currently part of the Coronavis cohort with an average age of 86 years, and in total, 272 samples have been obtained, of blood to test.